Augmentation cellular immune function early phase zidovudine treatment AIDS patients Twenty-five patients AIDS AIDS Clinical Trials Group Protocol low high dosages zidovudine moderate transient increases weeks lymphocyte blastogenesis interferon-gamma IFN-gamma production vitro response recombinant Immune simplex virus type antigens therapy Natural killer NK lysis uninfected human immunodeficiency virus-infected cells weeks IFN-gamma production immune parameter increases numbers cells weeks treatment limited efficacy zidovudine treatment AIDS patients moderate temporary increases nonspecific herpesvirus-specific lymphocyte responses NK cell function 